COVID-19

Hyperfine Swoop® System Referenced in France’s Largest Public Hospital Procurement Body to Facilitate Nationwide Purchases of Portable MRI Technology

UniHA approves framework agreement covering over 1,500 French public hospitals, facilitating the purchase of Swoop® AI-powered portable MRI systems over…

2 months ago

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October…

2 months ago

OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 Guidance

Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlookWARSAW, Ind., Oct. 09,…

2 months ago

Hemostemix Files for Ethics Approval of its Study of Vascular Dementia

Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is…

2 months ago

Hemostemix Files for Ethics Approval of its Study of Vascular Dementia

Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is…

2 months ago

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company…

2 months ago

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company…

2 months ago

Series A Round Valuation: ¥9 Billion: MEDIROM MOTHER Labs Inc. Decides to Make an Investment from Internal Investors

TOKYO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Yoshio Uekusa; hereinafter…

2 months ago

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1Approval is…

2 months ago